Skip to content
‹ Back to IndustriesSciences

On the way to Space, Billionaires Look for Business Partners

The world is in a new space race. This time, though, it is not the United States versus the Soviet Union; instead, it is Jeff Bezos versus Richard Branson versus Elon Musk. This billionaire space race, as it is being called, has resulted in the creation of just as many companies. Musk’s SpaceX and Branson’s…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Troy Camplin · BezosBlue OriginElon MuskScience
Share
On the way to Space, Billionaires Look for Business Partners

Key takeaways

01

The world is in a new space race.

02

This time, though, it is not the United States versus the Soviet Union; instead, it is Jeff Bezos versus Richard Branson versus Elon Musk.

03

This billionaire space race, as it is being called, has resulted in the creation of just as many companies.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The world is in a new space race. This time, though, it is not the United States versus the Soviet Union; instead, it is Jeff Bezos versus Richard Branson versus Elon Musk.

This billionaire space race, as it is being called, has resulted in the creation of just as many companies. Musk’s SpaceX and Branson’s Virgin Galactic may grab the headlines, but there is also Bezos’ Blue Origin, and Milner’s Breakthrough Starshot. The late Paul Allen also started Stratolaunch.

Each is aimed at somewhat different aspects of space travel, but one thing they all have in common is a competitive—and cooperative—spirit that is driving a great deal of technical innovation.

Companies like SpaceX are finding that it is important to partner with other companies to be successful. NASA and companies like Iridium have partnered with SpaceX to put satellites in orbit. Land Rover and Abu Dhabi, meanwhile, have chosen to partner with Virgin Galactic, who is also partnering with Boom Technology to create a supersonic passenger transporter. While SpaceX has NASA, Blue Origin is partnered with the Air Force for launch services.

There is a healthy need for space services and for creating strong partnerships to develop the technology needed, but what new technologies are on the horizon?

SpaceX has been having more and more success with its rockets, and it famously was able to land a rocket on a sea platform. Elon Musk has also been talking about going to Mars, and that will take some serious improvements in technology. In fact, SpaceX is currently working with NASA on developing a Mars-landing mission.

Blue Origin has developed New Shepard, a suborbital, reusable launch vehicle, and New Glenn, an orbital, reusable launch vehicle.

Virgin Galactic has long talked about the creation of a space plane that will make space tourism feasible. On Dec. 13, Virgin Galactic came a lot closer to realizing that dream when it was able to fly its VSS Unity to the edge of space.

With plans for the moon and Mars, including the possibility of 3D printing structures for people to potentially visit or inhabit, the sky is absolutely not the limit for these visionaries. While the space race between the USA and the USSR got man into space in the first place, and even placed a few men on the moon, the billionaires’ space race looks to take space technology, research, and exploration to new heights. Only time will tell what benefits all of this will bring.

For the latest news, videos, and podcasts in the Science Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – twitter.com/ScienceMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

TC
Troy Camplin
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Clinical data harmonization is the bottleneck for life sciences AI

Clinical data harmonization is the bottleneck for life sciences AI

Life sciences companies moving AI from experimentation to scale keep running into messy trial data. One study can draw on EDC, health records, eCOA tools, wearables and imaging, and data teams at pharma SMEs often spend up to 80% of their time wrangling it. Commentators point to lakehouse architectures and data-cleansing AI agents, though the agents are still at proof of concept.

  • 01Treat automation gains as proof-of-concept for now; evaluate AI/harmonization choices based on data readiness, governance, and whether the architecture supports traceability and regulatory needs.

Sep 26, 2026

CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

Contract Pharma reports bioTRAK data projecting CDMOs will install roughly 120 bioreactors by 2030. It says 71% of added volume is large-scale stainless steel, while 61% of systems are single-use.

  • 01Utilization discipline is still driving builds: BioTRAK’s Dawn Ecker told Contract Pharma expansion conversations typically start after a site is booked above ~80% for several years.

Sep 22, 2026

Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues in Pharmaceutical Commerce that life sciences firms must map airports, sea lanes, customs gateways and carriers alongside suppliers. Suppliers spread across countries can still share one air hub. The fix he describes is pre-qualified alternate routes and continuous review, with clinical trial shipments and cold-chain medicines the first cargo exposed when a corridor closes.

  • 01A supplier base spread across several countries can still be a single point of failure if every shipment routes through one airport hub or corridor; the sharper question for a logistics provider is which hubs each qualified lane actually depends on.
  • 02Gartner data cited by MD+DI gives a benchmark: 42% of procurement leaders rank supply disruption as their organization's top risk, with geopolitical issues including tariffs and regulatory changes ranking third.
  • 03A route map ages fast. Pharmaceutical Commerce published the mapping argument on July 24 and was reporting fresh Red Sea and Iran-related freight risk for pharma lanes by Aug. 10, which is the case for treating mapping as a recurring review rather than a project.

Sep 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

TC
Troy Camplin

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512